|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:affects
|
central nervous system
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05CF04
|
|
gptkbp:broadcastOn
|
Schedule IV (US)
|
|
gptkbp:contraindication
|
hypersensitivity to eszopiclone
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:drugClass
|
nonbenzodiazepine hypnotic
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericName
|
gptkb:eszopiclone
|
|
gptkbp:halfLife
|
6 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lunesta
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Sunovion_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:riskFactor
|
dependence
withdrawal symptoms
complex sleep behaviors
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
headache
drowsiness
dry mouth
unpleasant taste
|
|
gptkbp:usedFor
|
insomnia
|
|
gptkbp:bfsParent
|
gptkb:Sumitomo_Pharma
gptkb:Sumitomo_Dainippon_Pharma
|
|
gptkbp:bfsLayer
|
6
|